India’s Insulin Market Set For Sparks As Two Large Players Challenge The Dominance Of Sanofi-Aventis’ Lantus
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - For nearly a decade, the world's fourth-largest drug maker, Sanofi-Aventis, has had a free play in India in marketing its world-famous insulin brand Lantus, the only long-acting basal insulin, widely prescribed for its ability to slowly release insulin into the body. Now that could change as two large Indian players, Wockhardt and Biocon, are looking at chipping away some of this lucrative and growing market through their own brand launches
You may also be interested in...
Free Market Concept Not Applicable In Pharma Sector, Says India NPPA Chairman A.K. Banerjee: An Interview With PharmAsia News
While the need for price control of drugs continues to be a hot topic for debate, Dr A.K. Banerjee, the man carrying the onus of regulating drug prices in India as the chairman of the National Pharmaceuticals Pricing Authority, presents his viewpoint to PharmAsia News' India bureau on the need for price control in the country.
Free Market Concept Not Applicable In Pharma Sector, Says India NPPA Chairman A.K. Banerjee: An Interview With PharmAsia News
While the need for price control of drugs continues to be a hot topic for debate, Dr A.K. Banerjee, the man carrying the onus of regulating drug prices in India as the chairman of the National Pharmaceuticals Pricing Authority, presents his viewpoint to PharmAsia News' India bureau on the need for price control in the country.
Free Market Concept Not Applicable In Pharma Sector, Says India NPPA Chairman A.K. Banerjee: An Interview With PharmAsia News
Over half the population is uninsured, and unlike consumer durables where buying decisions depend on personal research and budget, in medicines their purchase decisions hinge on what is prescribed by doctors not by free choice, Banerjee argues.